CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2009
The primary objective of the trial is to evaluate efficacy and safety of delayed introduction (up to 30 days post-transplantation in patients without signs of acute rejection that had received an aIL-2 induction and MMF) of either cyclosporine or everolimus versus a 5-day delay of cyclosporine in combination with MMF.
Epistemonikos ID: ab6fb0479133fc8fee2d7cf2042198e613f17109
First added on: Nov 24, 2021